# RMC-6236-001: what clinicians are saying

> 196 statements from 50 sources (3 videos, 46 posts, 1 paper), 47 of them from 19 confirmed clinicians, each linked to its source. Commentary checked Nov 4, 2026.

## Report

- Trial: A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT ID: NCT05379985
- Registry: https://clinicaltrials.gov/study/NCT05379985
- Sponsor: Revolution Medicines, Inc.
- Phase: Phase 1/Phase 2
- Status: Recruiting
- Drugs tested: daraxonrasib (RMC-6236)
- Indication: RAS-mutant advanced solid tumors
- Version: v1.0.0, edition 1
- Accepted: 2026-11-04 UTC
- Last checked: 2026-11-04 UTC
- Release hash: 5c02680ee9bf243915ef2f4967faf69e67ae10262364ae4e56abe96a4102016b

## Counts

- Commentary sources screened: 87
- Sources cited by verified statements: 50
- Verified statements: 196
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 47
- Findings: 9
- Named people in screened sources (unnamed speakers and accounts not counted): 34
- Voices cited: 34
- Cited voices with a verified identity: 29
- Cited clinicians, voices with a confirmed clinical role (the abstract's clinicians): 19
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 19
- By role and specialty (the abstract's specialty counts):
  - 15 physician, Medical oncology
  - 2 physician
  - 1 physician, Cardiology
  - 1 physician, Pathology
- Organisational or shared accounts (not counted as people): 11

A verified identity says who a voice is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified voices without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

RMC-6236-001 examines RMC-6236 safety in advanced solid tumors with specific RAS mutations; discussion of non-small cell lung cancer (NSCLC) combines support for activity beyond G12C with questions about the highlighted response estimate. The report cites 19 physicians, including 15 medical oncologists, and a contributor described in the source as involved in the trial. Further questions concern lower NSCLC dosing and whether previously treated pancreatic ductal adenocarcinoma activity warrants practice change. How can teams explain cohort-specific benefit estimates and toxicity burden while separating evidence from access?

## Open Medical Affairs question

How can Medical Affairs preserve cohort-specific benefit estimates, the practical burden of toxicity and the distinction between evidence and access in the same conversation?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Speakers welcome NSCLC activity beyond G12C; one discussion challenges the highlighted 42% response estimate
- F2. Speakers favor a lower NSCLC dose on tolerability grounds and stress the burden of toxicity
- F3. Speakers differ on whether previously treated PDAC activity is enough to change practice
- F4. Speakers describe manageable PDAC toxicity as work-intensive; one clinician asks whether skin toxicity is unfamiliar
- F5. Speakers see a conceptual advance and discuss a possible RAS-treatment platform
- F6. Speakers flag resistance and sequencing gaps; one also highlights CNS activity
- F7. Speakers welcome first-line PDAC monotherapy, while combination views range from enthusiasm to doubt
- F8. One clinician asks about off-label NSCLC access; other sources stress route-specific restrictions
- F_context_without_trial_name. How do account-authored assessments frame daraxonrasib activity and severe adverse events in NSCLC and PDAC?

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers named counts every name a finding's statements carry, of any role and including names not yet matched to a person, so it is not the report's count of cited voices or confirmed clinicians and can be larger.

| Finding | Statements | Passages | Sources | Speakers named (any role) | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 23 | 23 | 7 | 5 | 4 |
| F2 | 30 | 31 | 9 | 6 | 4 |
| F3 | 36 | 27 | 16 | 20 | 4 |
| F4 | 12 | 11 | 7 | 8 | 3 |
| F5 | 18 | 21 | 11 | 9 | 4 |
| F6 | 14 | 15 | 7 | 5 | 4 |
| F7 | 16 | 15 | 9 | 9 | 5 |
| F8 | 15 | 16 | 10 | 6 | 5 |
| F_context_without_trial_name | 2 | 2 | 2 | 2 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 12 | 3 | 0 | 2 | 6 | 25 | 1 | 6 posts and articles, 1 podcast or video | yes |
| F2 | 18 | 1 | 0 | 3 | 8 | 32 | 2 | 8 posts and articles, 1 podcast or video | yes |
| F3 | 21 | 4 | 0 | 4 | 7 | 40 | 0 | 15 posts and articles, 1 podcast or video | yes |
| F4 | 10 | 1 | 0 | 0 | 1 | 13 | 0 | 7 posts and articles | yes |
| F5 | 12 | 1 | 0 | 3 | 2 | 26 | 0 | 8 posts and articles, 2 podcasts and video, 1 publication | yes |
| F6 | 11 | 3 | 0 | 0 | 0 | 16 | 0 | 4 posts and articles, 2 podcasts and video, 1 publication | yes |
| F7 | 8 | 3 | 1 | 2 | 2 | 17 | 2 | 8 posts and articles, 1 publication | yes |
| F8 | 7 | 1 | 1 | 1 | 5 | 21 | 0 | 7 posts and articles, 3 podcasts and video | yes |
| F_context_without_trial_name | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 2 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs: F2 (11 shared claims), F3 (2 shared claims), F4 (2 shared claims), F_context_without_trial_name (1 shared claims)
- Primary endpoint: Number of Participants with Dose-Limiting Toxicity (DLT): no finding draws on it directly
- Secondary endpoints: F1 (7 shared claims), F3 (12 shared claims), F6 (1 shared claims), F7 (2 shared claims), F_context_without_trial_name (1 shared claims)
- Population and setting: F1 (3 shared claims), F2 (1 shared claims), F3 (3 shared claims), F5 (3 shared claims), F6 (6 shared claims), F7 (1 shared claims), F8 (1 shared claims)
- The comparison: F1 (5 shared claims), F2 (1 shared claims), F3 (6 shared claims), F7 (2 shared claims)
- Safety and tolerability: F2 (10 shared claims), F3 (1 shared claims), F4 (12 shared claims), F5 (1 shared claims)
- Design and conduct: F1 (7 shared claims), F3 (3 shared claims)

## Abbreviations

- AE: adverse event
- CNS: central nervous system
- CRC: colorectal cancer
- DLT: dose-limiting toxicity
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- PDAC: pancreatic ductal adenocarcinoma

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 9 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 196 | Paid |
| Who said each statement, with each cited voice's role and what confirmed it (NPI registry or staff page) | 34 | Every edition |
| Trial aspects mapped | 13 | Free |
| Sources with links | 50 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
| Verified speaker IDs as data (NPI, social and scholarly IDs) | 29 | 12-month plan add-on |

Every edition, the free report included, names who said each statement, as the source shows them. Each named voice's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 19 of the 34 cited voices have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, never for outreach or targeting, and it does not unlock who said what.

## Trial aspects

12 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs | discussed | 15 | 10 |
| Primary endpoint: Number of Participants with Dose-Limiting Toxicity (DLT) | no commentary found | 0 | 0 |
| Secondary endpoints | discussed | 24 | 19 |
| Population and setting | discussed | 18 | 11 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 14 | 11 |
| Safety and tolerability | discussed | 23 | 9 |
| Design and conduct | discussed | 13 | 4 |
| Dose optimization and the efficacy–tolerability trade-off | discussed | 11 | 7 |
| Broader RAS coverage, biological relevance and platform interpretations | discussed | 15 | 10 |
| ctDNA, resistance, prior RAS-inhibitor sequencing and CNS questions | discussed | 11 | 6 |
| First-line PDAC monotherapy and distinct combination strategies | discussed | 14 | 8 |
| Access, eligibility, patient support and indication-specific communication | discussed | 15 | 10 |
| Historical benchmarks, randomized corroboration and thresholds for practice change | discussed | 29 | 14 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 75 | 39 |
| Bluesky threads | 5 | 3 |
| LinkedIn posts | 4 | 4 |
| YouTube | 3 | 3 |
| Publications (primary source, cited for context) | not screened | 1 |

- Screened window: 2022-11-11 to 2026-10-07
- Cited window: 2022-11-11 to 2026-09-14
- Retrieved: 2026-11-04

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Registry: NCT05379985 (https://clinicaltrials.gov/study/NCT05379985)
- Study IDs: RMC-6236-001
- Sponsor: Revolution Medicines, Inc.
- Design: Phase 1/Phase 2 · interventional, na, single group, phase1, phase2
- Status: Recruiting
- Enrollment: 754 (estimated)
- Start: 2022-05-31 (actual)
- Primary completion: 2027-05-31 (estimated)
- Primary endpoint: Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs (up to 2.5 years)
- Primary endpoint: Number of Participants with Dose-Limiting Toxicity (DLT) (21 days)
- Intervention: RMC-6236 (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on treatment-history uncertainty in commentary about RAS-targeted therapy for progressive pancreatic cancer.
- Not yet captured in this edition: a remark on biomarker-defined combination-trial options and geographic access for patients with non-small cell lung cancer.
- Not yet captured in this edition: a view on first-line daraxonrasib plus chemotherapy in RAS-mutant metastatic pancreatic cancer.
- Not yet captured in this edition: a view on testing chemotherapy-free treatment against standard care in frontline pancreatic cancer.
- Not yet captured in this edition: a view on chemotherapy-free treatment versus standard care in frontline pancreatic cancer.
- Not yet captured in this edition: a view on the value of treatment response specifically for patients who respond.
- 79 passages in 48 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 57 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 100 sources about other trials or topics are not included; 398 sources that may describe the trial without naming it were not read.
- This report describes the sources reviewed for this edition, not all HCPs or all public discussion. Some potentially relevant sources were not read, and some passages were not fully assessed; unnamed trial references may also have been missed.
- Repeated cross-platform posts, reposts, organizational summaries and relayed presentations are not independent HCP votes. The frequency of a view cannot be interpreted as its prevalence in clinical practice.
- Some authors' clinical roles are unconfirmed, and video speakers are not identified. Those contributions are described by source rather than assigned inferred credentials or identities.
- RMC-6236-001 cohorts, doses, treatment lines and data summaries differ across sources. Historical comparisons and separate phase 3 or combination-study commentary do not establish comparative results for the target study.
- Several numerical or textual ambiguities remain, including a 136-versus-137 NSCLC participant count across posts, unclear PDAC outcome denominators in one abbreviated post, inconsistent spoken dose-toxicity figures and an uncertain adverse-event term.
- No protocol or exact regulatory label was available. Regulatory, guideline and access statements remain dated commentary rather than a verified current status assessment.
- The discussion is concentrated in PDAC and NSCLC. Little can be concluded here about HCP interpretation of CRC, other solid-tumor cohorts or the specific dose-limiting-toxicity endpoint.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-04 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-04 UTC. No changes.

## Offer

- Size: Standard · 196 verified statements · 47 from 19 confirmed clinicians
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $2,200
- 6 months of updates: $3,100
- 12 months of updates: $4,400
- Optional verified speaker identities (12-month updates only, product updates-12-identities; speakers are named and described in every report): the NPI and other verified IDs, to check that each statement is attributed to the right person, never for outreach or targeting, at $15 per identity-verified person in the edition at purchase (29 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/rmc-6236-001-nct05379985
- Agents: POST https://www.erudio.com/api/orders with {"report": "rmc-6236-001-nct05379985", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=rmc-6236-001-05379985

## Cite

Erudio Health. RMC-6236-001 (NCT05379985): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 4, 2026. https://www.erudio.com/reports/rmc-6236-001-nct05379985

## Machine access

- JSON: https://www.erudio.com/reports/rmc-6236-001-nct05379985.json
- Markdown: https://www.erudio.com/reports/rmc-6236-001-nct05379985.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/rmc-6236-001-nct05379985/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "rmc-6236-001-nct05379985"}`